Biotech
Monday, August 26th, 2024 5:24 pm EDT
Key Points
- Launch of Stelo: Dexcom has launched Stelo, an over-the-counter continuous glucose monitor (CGM) designed primarily for individuals with prediabetes or Type 2 diabetes who do not use insulin, marking the company’s first CGM that does not require a prescription.
- User Experience and Functionality: Stelo, worn on the upper arm and connected to a smartphone app, provides real-time glucose monitoring and alerts users to significant spikes in glucose levels, helping them make informed dietary choices and develop healthier habits.
- Market Impact: By targeting the large population of Americans with prediabetes or Type 2 diabetes, Stelo represents Dexcom’s entry into a potentially lucrative new market, offering broader access to glucose monitoring without the need for insurance or prescriptions.
Dexcom recently launched Stelo, its new over-the-counter continuous glucose monitor (CGM), available for purchase in the U.S. for individuals with prediabetes or Type 2 diabetes who do not use insulin. Unlike Dexcom’s previous CGMs, Stelo does not require a prescription, making it accessible to millions of Americans with prediabetes or Type 2 diabetes who previously faced barriers to obtaining these devices. Users can purchase a one-month supply of Stelo for $99 or subscribe for $89 per month, with flexible payment options through health savings and flexible spending accounts.
Stelo is designed to help users monitor their glucose levels in real-time, offering insights that can help them make healthier dietary choices and habits. The device, worn on the upper arm, is small, waterproof, and lasts for 15 days before needing replacement. It wirelessly transmits data to a smartphone app, where users can view their glucose levels, trends, and receive notifications about significant spikes. The app includes educational materials that guide users on how to manage their glucose levels effectively.
The U.S. Food and Drug Administration (FDA) approved Stelo in March, making it the first over-the-counter CGM to gain clearance, although Abbott has since released similar devices. Dexcom has partnered with Amazon to handle Stelo deliveries, and users can manage their subscriptions through the app. Stelo’s release marks Dexcom’s entry into the lucrative prediabetes market, potentially expanding its reach beyond traditional diabetes management.
The Stelo app is user-friendly, providing clear instructions for sensor application and data tracking. Users can log meals, activities, and other notes to understand how their actions affect their glucose levels. The app also offers integration with Apple Health and Android’s Health Connect for importing sleep and activity data, enhancing the overall monitoring experience.
In testing, Stelo has proven easy to use, with the app delivering timely insights without overwhelming the user with data or notifications. The device’s algorithm becomes more personalized over time, helping users identify patterns and make informed decisions about their health. Stelo’s combination of simplicity, accessibility, and effectiveness makes it a strong option for those looking to gain better control over their glucose levels, whether they have prediabetes, Type 2 diabetes, or simply want to monitor their health.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/08/26/dexcom-launches-stelo-its-first-over-the-counter-continuous-glucose-monitor.html
